Your browser doesn't support javascript.
loading
Short-term chemosensory distortions and phantoms in COVID-19.
Gurrola, José G; Chang, Jolie L; Roland, Lauren T; Loftus, Patricia A; Cheung, Steven W.
Afiliación
  • Gurrola JG; Department of Otolaryngology-Head and Neck Surgery University of California, San Francisco San Francisco California USA.
  • Chang JL; Department of Otolaryngology-Head and Neck Surgery University of California, San Francisco San Francisco California USA.
  • Roland LT; Department of Otolaryngology-Head and Neck Surgery University of California, San Francisco San Francisco California USA.
  • Loftus PA; Department of Otolaryngology-Head and Neck Surgery University of California, San Francisco San Francisco California USA.
  • Cheung SW; Department of Otolaryngology-Head and Neck Surgery University of California, San Francisco San Francisco California USA.
Laryngoscope Investig Otolaryngol ; 6(2): 172-176, 2021 Apr.
Article en En | MEDLINE | ID: mdl-33821217
Objective: To identify differentiation features of chemosensory dysfunction in COVID-19 infection and their primary drivers. Study Design: Cross-sectional cohort comparison. Methods: A national anonymous survey was used to query participants regarding nasal symptoms and chemosensory dysfunction including sensitivity levels, and presence or absence of distortions and phantoms within the 6-week time window surrounding their COVID-19 testing and survey completion. Results: Three-hundred and sixty-four respondents who reported COVID-19 positive (COVID+; n = 176) or COVID-19 negative (COVID-; n = 188) test results completed the survey. The COVID+ cohort had higher occurrence rates for: (a) chemosensory sensitivity impairments (67.0% vs 30.3%; P < .01), where the rate of complete loss of smell (anosmia) or taste (ageusia) was higher (35.8% vs 4.8%; P < .01), and (b) chemosensory distortions (39.8% vs 19.1%; P < .01), where the rate of anosmia or ageusia with distortions was also higher in the COVID+ cohort (19.9% vs 2.7%; P < .01). Occurrence rates in the two cohorts were similar for chemosensory phantoms (COVID+ 17.0%, COVID- 18.6%; P = .70) and nasal discharge or stuffiness in the presence of sensitivity impairment (COVID+ 63.6%, COVID- 52.6%; P = .17). Conclusion: Chemosensory dysfunction in COVID-19 is associated with higher rates of smell or taste sensitivity impairments and distortions. Higher rates of anosmia and ageusia drive these key findings. Chemosensory phantoms and nasal symptoms in the presence of sensitivity impairment occur at rates that should demand clinical attention, but they do not appear to be specific to COVID-19 positivity. Level of Evidence: 2b.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Laryngoscope Investig Otolaryngol Año: 2021 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Laryngoscope Investig Otolaryngol Año: 2021 Tipo del documento: Article Pais de publicación: Estados Unidos